注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Xenetic Biosciences Inc是一家生物制药公司。该公司专注于开发XCART,一种针对患者和肿瘤特异性新抗原的个性化嵌合抗原受体(CAR)T平台技术。该公司正在推进针对单个患者恶性肿瘤细胞表面B细胞受体的细胞治疗,用于治疗B细胞性非霍奇金淋巴瘤。该公司利用其药物递送平台PolyXen与生物技术和制药公司合作。其产品线包括XCART和ErepoXen,或多唾液酸促红细胞生成素(PSA-EPO)。(PSA-EPO)使用其PolyXen平台技术治疗慢性肾病患者的贫血。它旨在通过延长治疗药物在体内的循环半衰期来降低给药频率。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Adam E. Logal | 45 | 2017 | Independent Chairman of the Board |
Jeffrey F. Eisenberg | 57 | 2016 | CEO, President & Director |
James Eric Callaway | 66 | 2017 | Independent Director |
Firdaus Jal Dastoor | 70 | 2014 | Independent Director |
Dmitry Dmitrievich Genkin | 56 | 2016 | Non-Executive Director |
Roger D. Kornberg | 76 | 2016 | Independent Director |
Alexey Andreevich Vinogradov | 52 | 2019 | Independent Director |
Matthew Frigault | - | 2019 | Member of Scientific Advisory Board |
Guenther Koehne | - | 2019 | Member of Scientific Advisory Board |
Grigory G. Borisenko | 54 | 2019 | Independent Non-Executive Director |
Maksim Mamonkin | - | 2020 | Member of Scientific Advisory Board |
Allan Tsung | - | 2022 | Member of Scientific Advisory Board |
Jonathan Spicer | - | 2022 | Member of Scientific Advisory Board |
Moshe Mizrahy | 70 | 2023 | Independent Non Executive Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核